Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Saudi Pharm J ; 26(1): 53-63, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29379333

ABSTRACT

A two factor three level factorial design was used to investigate the effects of carbopol and cationic hydrophilic polymers which have a common use in buccal drug formulations. Statistical models with interaction terms were derived to evaluate influence of carbopol (X1) and chitosan (X2) on tablet disintegration (Y1) and dissolution (Y2), mechanical properties (Y3), swelling (Y4). Tablet disintegration studies were carried out using two different pH environments within buccal region pH limits and also two different commonly used dissolution methods for buccal tablets were also investigated to compare the effect of polymer type on dissolution. Polymer type and ratio affect the characteristics of the buccal tablets due to their different physicochemical behavior at buccal pH. Also significant variances between dissolution profiles for buccal tablets, using either USP Paddle or flow through cell methods were found. These results indicate that both polymer type and ratio as well as combination of them effects the drug behavior in different ways.

3.
Clin Exp Allergy ; 38(6): 995-1002, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18384430

ABSTRACT

BACKGROUND: Studies on cow's milk allergy (CMA) in adults are scarce. Little is known about the clinical symptoms, eliciting doses (ED), and allergens involved. OBJECTIVE: The aim of this study was to analyse the clinical symptoms, ED and allergen recognition in adult CMA patients, compared with cow's milk (CM)-sensitized, but tolerant controls. METHODS: Adult CMA patients were evaluated by standardized questionnaires (n=30), skin prick tests (SPTs) and specific IgE for CM allergens (n=18), and a double-blind placebo-controlled food challenge (DBPCFC, n=10). A control group (n=25) of CM-sensitized, but tolerant adults was included. RESULTS: The majority of CMA patients (20/30, 67%) reported severe symptoms. In all patients participating in DBPCFC, CMA was confirmed. ED for subjective symptoms (0.3-300 mg CM protein) were significantly lower than that for objective symptoms (300-9000 mg CM protein). The severity of CMA by history and ED was not correlated with SPT or IgE. Patients had higher SPT reactivity than controls for CM, alpha-lactalbumin and beta-lactoglobulin (P=0.002, P=0.014 and P=0.004) but not for casein. Specific IgE to CM tended to be higher (P=0.068) and IgE to casein was higher in patients than that in controls (P=0.016). No difference was observed for IgE to alpha-lactalbumin and beta-lactoglobulin. CONCLUSION: Adult CMA is severe in nature. ED are low, starting from 0.3 mg CM protein. Patients with CMA recognize the same major allergens (casein and whey proteins) as controls, but display a stronger SPT and IgE reactivity.


Subject(s)
Caseins/adverse effects , Milk Hypersensitivity/immunology , Milk Proteins/adverse effects , Administration, Oral , Adolescent , Adult , Aged , Animals , Case-Control Studies , Cattle , Double-Blind Method , Female , Humans , Immune Tolerance/immunology , Immunoglobulin E/blood , Lactalbumin/adverse effects , Lactoglobulins/adverse effects , Male , Middle Aged , Milk Hypersensitivity/blood , Milk Hypersensitivity/classification , Milk Hypersensitivity/complications , Severity of Illness Index , Skin Tests , Statistics, Nonparametric , Surveys and Questionnaires , Whey Proteins
4.
Clin Exp Allergy ; 37(1): 108-15, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17210048

ABSTRACT

BACKGROUND: Recognition of specific peanut allergens or the diversity of IgE binding to peanut allergens may play a role in the elicitation of severe allergic reactions. OBJECTIVE: To investigate whether sensitization to individual allergens Ara h 1, Ara h 2, Ara h 3 and Ara h 6 is correlated with clinical severity. METHODS: The reactivity of purified peanut allergens was measured by skin prick test (SPT) and by IgE immunoblot in 30 patients. The results were related to the clinical reactivity by history, and in 25 of them to the eliciting dose (ED). RESULTS: The majority of patients recognized Ara h 2 and Ara h 6. Patients with severe symptoms had a higher SPT response to Ara h 2 and Ara h 6 at low concentrations (0.1 micro g/mL) and to Ara h 1 and Ara h 3 at higher concentrations (100 micro g/mL), compared with patients with mild symptoms. They also recognized a greater number of allergens and showed a higher cumulative SPT response compared with patients with mild symptoms. No significant differences were observed between patients with a low or high ED. CONCLUSIONS: Ara h 2 and Ara h 6 appeared to be more potent than Ara h 1 and Ara h 3. Both SPT reactivity to low concentrations of Ara h 2 and Ara h 6 and to higher concentrations of Ara h 1 and Ara h 3 were shown to be indicative of severe symptoms.


Subject(s)
Peanut Agglutinin , Peanut Hypersensitivity/diagnosis , 2S Albumins, Plant , Adolescent , Adult , Aged , Allergens/immunology , Antigens, Plant , Dose-Response Relationship, Immunologic , Double-Blind Method , Female , Glycoproteins/immunology , Humans , Immunoglobulin E/blood , Male , Membrane Proteins , Middle Aged , No-Observed-Adverse-Effect Level , Peanut Agglutinin/immunology , Peanut Hypersensitivity/immunology , Plant Proteins/immunology , Predictive Value of Tests , Seed Storage Proteins , Skin/immunology , Skin Tests , Statistics, Nonparametric
5.
Toxicon ; 45(1): 43-52, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15581682

ABSTRACT

In the present study, crude venom of Mesobuthus gibbosus (Buthidae), a scorpion distributed all over Anatolia was isolated and purified by the Sephadex G-50 gel filtration and high pressure liquid chromatographic (HPLC) separation. Two of the five fractions (fractions 4 and 5) obtained from the Sephadex G-50 filtration and detected as lethal on mice and Musca domestica larvae in in vivo toxicity tests, were independently subjected to the HPLC separation. Only one of seven fractions (fraction 5.5*) obtained from the HPLC separation of the fraction 5 was found to be extremely lethal. Sodium dodecylsulfate polyacrylamide gel electrophoretic (SDS-PAGE) analysis of the crude venom and its chromatographic fractions demonstrated that crude venom consisted of peptides with molecular weights of 6500-210,000 Da. The neurotoxic fraction 5.5* appeared as a single band of 28,000 Da and two bands of 6200 and 22,000 Da in SDS-PAGE under non-reducing and reducing conditions, respectively, suggesting that it might consist of two chains attached by a disulfide bridge. Fractions 5 and 5.5* inhibited monoamine oxidase A (MAO-A) of rat liver reversibly and non-competitively, in a concentration-dependent manner. Fraction 5.5* appeared as a potent and specific MAO-A inhibitor with a Ki value of 0.12 mg venom proteinml(-1). The inhibitory effect of venom peptide 5.5* on MAO-A was found to be dependent on the preincubation time suggesting that the peptide binds to some site other than the substrate-binding site. Results of the present study demonstrated that M. gibbosus venom contains a peptide with specific MAO-A inhibitory activity which may be responsible for the anxiogenic effects of the scorpion venoms on animals and humans.


Subject(s)
Monoamine Oxidase Inhibitors/pharmacology , Scorpion Venoms/pharmacology , Animals , Blood Platelets/enzymology , Dose-Response Relationship, Drug , Houseflies/drug effects , Humans , Kinetics , Larva/drug effects , Liver/enzymology , Mice , Mice, Inbred C57BL , Peptides/isolation & purification , Peptides/pharmacology , Rats , Scorpion Venoms/chemistry
6.
Tissue Eng ; 4(4): 353-63, 1998.
Article in English | MEDLINE | ID: mdl-9916168

ABSTRACT

Poly(d,l)-lactide (PDLLA) homopolymer, with an average molecular weight of 20,000 daltons, was produced by the ring-opening polymerization of d,l-lactide in the presence of SnCl(2).2H(2)O as the catalyst. The PDLLA sponges loaded with chloramphenicol were prepared by a solvent evaporation technique. The drug loadings achieved were 14.84 and 25.23 mg for the PDLLA sponges with 35 and 70 mg total weights, respectively. These sponges were implanted in Wistar rats, and in vivo degradation, drug release, and tissue reactions were followed. The PDLLA sponges carrying no drug degraded with time linearly. Almost 80% of the sponges were degraded in about 180 days. While the drug-loaded PDLLA sponges were degraded much faster in 4 weeks (about 35% of the matrix was degraded), then the degradation slowed down significantly. Drug release from the sponges was parallel to the degradation. Almost 60% of the loaded drug released in 4 weeks. There were no acute inflammatory reactions in the initial period, either for the plain or for the drug-loaded PDLLA sponges. Macrophages and multinuclear giant cells start to appear after 7 days of implantation. The fibroblastic activity also started after the same period. After that, there were decreases in the number of some cells (neutrophils, lymphocytes, and macrophages), while multinuclear giant cells and fibroblastic activities gradually increased. Granulation tissue started at about 1 month, and new connective tissue was gradually formed until 180 days of implantation. There were significant numbers of inflammatory cells after 60 days, which were replaced by fibroblasts after 180 days. There was almost no significant neovascularization after 180 days, but implant fragmentation gradually increased (which slows the degradation) with time. It was concluded that this novel drug release sponge may be safely and effectively used as an active soft tissue-filling material.


Subject(s)
Chloramphenicol/pharmacokinetics , Polyesters/pharmacokinetics , Prostheses and Implants , Soft Tissue Injuries/surgery , Surgical Sponges , Wound Healing , Animals , Chloramphenicol/administration & dosage , Connective Tissue/pathology , Drug Implants/adverse effects , Evaluation Studies as Topic , Foreign-Body Reaction/etiology , Foreign-Body Reaction/pathology , Granulation Tissue/pathology , Leukocytes/pathology , Macrophages/pathology , Male , Molecular Weight , Polyesters/chemistry , Prostheses and Implants/adverse effects , Rats , Rats, Wistar , Surgical Sponges/adverse effects , Surgical Wound Infection/prevention & control
8.
Diagn Imaging ; 48(1): 32-40, 1979.
Article in English | MEDLINE | ID: mdl-535511

ABSTRACT

In 19 patients with symptoms suggestive of a cervicobrachial syndrome due to degernative lesions of the cervical spine, a CT scan was made after intrathecal administration of metrizamide. The images thus obtained supply adequate information on the extent of bone apposition, if any, on the degree of displacement and compression of the spinal cord, and on the condition of the intervertebral foramina. A CT scan is indicated in the case of discrepancy between myelographic findings and clinical diagnosis. In the case of recurrent postoperative symptoms, too, CT scans have proved to supply valuable information.


Subject(s)
Cervical Vertebrae/diagnostic imaging , Myelography/methods , Spinal Diseases/diagnostic imaging , Tomography, X-Ray Computed , Aged , Contrast Media , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Tomography, X-Ray Computed/methods
9.
Diagn Imaging ; 48(2): 71-9, 1979.
Article in English | MEDLINE | ID: mdl-535516

ABSTRACT

Of a series of 20 patients in whom CT scans revealed lesions of the vertebral column, 6 cases are discussed which confirm the efficacy of this method of investigation. Good information is obtained in particular on pathological processes in which optimally exact localization is required preoperatively and in tumor relapses. CT scanning is also indicated when myelography proves to be impossible, e.g., due to adhesions. Computer-assisted myelography, however, does not yet seem suitable to be used as a routine procedure.


Subject(s)
Myelography/methods , Spinal Cord Diseases/diagnostic imaging , Spinal Diseases/diagnostic imaging , Tomography, X-Ray Computed , Adult , Female , Humans , Male , Middle Aged , Neurofibroma/diagnostic imaging , Spinal Cord Neoplasms/diagnostic imaging
SELECTION OF CITATIONS
SEARCH DETAIL
...